Unknown

Dataset Information

0

Daunorubicin resensitizes Gram-negative superbugs to the last-line antibiotics and prevents the transmission of antibiotic resistance.


ABSTRACT: Although meropenem, colistin, and tigecycline are recognized as the last-line antibiotics for multidrug-resistant Gram-negative bacteria (MDR-GN), the emergence of mobile resistance genes such as blaNDM, mcr, and tet(X) severely compromises their clinical effectiveness. Developing novel antibiotic adjuvants to restore the effectiveness of existing antibiotics provides a feasible approach to address this issue. Herein, we discover that a Food and Drug Administration (FDA)-approved drug daunorubicin (DNR) drastically potentiates the activity of last-resort antibiotics against MDR-GN pathogens and biofilm-producing bacteria. Furthermore, DNR effectively inhibits the evolution and spread of colistin and tigecycline resistance. Mechanistically, DNR and colistin combination exacerbates membrane disruption, induces DNA damage and the massive production of reactive oxygen species (ROS), ultimately leading to bacterial cell death. Importantly, DNR restores the effectiveness of colistin in Galleria mellonella and murine models of infection. Collectively, our findings provide a potential drug combination strategy for treating severe infections elicited by Gram-negative superbugs.

SUBMITTER: Cai J 

PROVIDER: S-EPMC10206174 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Daunorubicin resensitizes Gram-negative superbugs to the last-line antibiotics and prevents the transmission of antibiotic resistance.

Cai Jinju J   Deng Tian T   Shi Jingru J   Chen Chen C   Wang Zhiqiang Z   Liu Yuan Y  

iScience 20230504 6


Although meropenem, colistin, and tigecycline are recognized as the last-line antibiotics for multidrug-resistant Gram-negative bacteria (MDR-GN), the emergence of mobile resistance genes such as <i>bla</i><sub>NDM</sub>, <i>mcr</i>, and <i>tet</i>(X) severely compromises their clinical effectiveness. Developing novel antibiotic adjuvants to restore the effectiveness of existing antibiotics provides a feasible approach to address this issue. Herein, we discover that a Food and Drug Administratio  ...[more]

Similar Datasets

| S-EPMC10842942 | biostudies-literature
| S-EPMC4980087 | biostudies-literature
| S-EPMC10269726 | biostudies-literature
| S-EPMC11923103 | biostudies-literature
| S-EPMC4033650 | biostudies-literature
| S-EPMC5570306 | biostudies-literature
| S-EPMC10128002 | biostudies-literature
| S-EPMC6026146 | biostudies-literature
| S-EPMC8001261 | biostudies-literature
| S-EPMC5750058 | biostudies-literature